Company Summary - BTG PLC (LSE:BGC)
345.70p
4.80p
(1.39%)
FTSE 250 Pharmaceuticals & BiotechnologyMarket cap: £1,131.452m
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Development and commercialisation of life science technologies
| Financials - Interim (17/11/2011) | ||
|---|---|---|
| Turnover | £m | 110.6 |
| Pre-tax Profit | £m | 19.5 |
| EPS | p | 9.61 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Garry Watts | Chairman |
| Dr. Pamela Makin | Chief Executive |
| Rolf Soderstrom | Finance Director |
Products Brands & Subsidiaries
Products & Brands
ABIO-0801; AZD9773; AcadraTM; Alemtuzumab; BGC20-0134; Bead BlockTM; CB7630; CellBeadTM; CroFab; DC Bead; DigiFab; JuvidexTM...
Subsidiaries
BTG Investment (Holdings) Ltd; BTG International Ltd; Provensis Ltd; BTG International (Holdings) Ltd; Protherics Utah Inc...
Broker Sentiment (6 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Total Voting Rights | 31/01/2012 |
| Research Update | 30/01/2012 |
| Total Voting Rights | 26/01/2012 |